Donald Trump’s victory in Tuesday’s presidential election, together with the defeat of a California ballot measure, has one industry breathing a sigh of relief, at least for now: pharmaceuticals.

And you thought the inflation rate was low.

Americans' growing alarm over rising prescription drug costs will pressure a new U.S. administration and Congress to take action on pharmaceutical pricing, industry executives and healthcare experts say.

Republican control of the White House and Congress erodes the possibility of federal action to control the price of prescription drugs, health policy experts say.

Hospital and insurance companies that have benefited from the Affordable Care Act’s expansion of Medicaid coverage saw a sharp fall in their stock prices on fears a Trump administration could roll back that expansion.

Millions of low-income Americans on Medicaid could lose their health coverage if President-elect Donald Trump and a Republican-controlled Congress follow through on GOP proposals to cut spending in the state-federal insurance program.